Clinical trial
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and…
NCT00196937 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00196937 |
|---|---|
| Title | Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 |
| Official title | Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | Cervarix |
| Enrollment | 667 |
| Start date | Oct 7, 2004 |
| Primary completion | Dec 15, 2005 |
| Completion | Dec 15, 2005 |
| First posted | Sep 20, 2005 |
| Last update posted | Dec 11, 2019 |
| Countries | Germany, Poland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: